Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887144 | 0.87 | PTGS2 (0.34) | MAPT | |
| SCHEMBL5887164 | 0.87 | ALDH1A1 (0.35) | KIF11ALDH1A1KDM1ANPBWR1BACE1 | |
| SCHEMBL5886998 | 0.84 | ALDH1A1 (0.33) | KIF11ALDH1A1KDM1ANPBWR1BACE1 | |
| SCHEMBL5887471 | 0.82 | KIF11 (0.34) | KIF11ALDH1A1KDM1ANPBWR1BACE1 | |
| SCHEMBL5887236 | 0.79 | ESR2 (0.35) | — | |
| SCHEMBL5887188 | 0.75 | ALDH1A1 (0.33) | KIF11ALDH1A1KDM1ANPBWR1BACE1 | |
| SCHEMBL4009121 | 0.72 | ALDH1A1 (0.33) | ALDH1A1MAPTACHE | |
| SCHEMBL1044865 | 0.71 | KIF11 (0.61) | KIF11ALDH1A1NPBWR1CYP1A1CYP1B1 | |
| SCHEMBL13019482 | 0.71 | KIF11 (0.61) | KIF11ALDH1A1NPBWR1CYP1A1CYP1B1 | |
| SCHEMBL17110032 | 0.71 | KIF11 (0.61) | KIF11ALDH1A1NPBWR1CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| US-20050026903-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026903-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GLP1R | KIF11 3409/4885ALDH1A1 1501/4885KDM1A 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.